vs
Side-by-side financial comparison of Pediatrix Medical Group, Inc. (MD) and Enpro Inc. (NPO). Click either name above to swap in a different company.
Pediatrix Medical Group, Inc. is the larger business by last-quarter revenue ($493.8M vs $295.4M, roughly 1.7× Enpro Inc.). Pediatrix Medical Group, Inc. runs the higher net margin — 6.8% vs -10.8%, a 17.7% gap on every dollar of revenue. On growth, Enpro Inc. posted the faster year-over-year revenue change (14.3% vs -1.7%). Over the past eight quarters, Enpro Inc.'s revenue compounded faster (7.1% CAGR vs -0.1%).
Pediatrix Medical Group, Inc. is a leading U.S. specialized medical service provider focusing on maternal-fetal care, neonatology, pediatric cardiology and other pediatric subspecialties. It partners with U.S. healthcare facilities to deliver evidence-based care to women, newborns and children.
Enpro is a US-based industrial technology company that designs and manufactures products and materials for technology-intensive sectors. The company serves industries such as semiconductors, aerospace, power generation, heavy-duty trucking, agricultural machinery, chemical processing, pulp and paper, and life sciences from 61 primary manufacturing facilities located in 12 countries, worldwide. It is organized under three segments: Sealing Technologies, Advanced Surface Technologies, and Engin...
MD vs NPO — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $493.8M | $295.4M |
| Net Profit | $33.7M | $-32.0M |
| Gross Margin | — | 42.1% |
| Operating Margin | 9.9% | 11.2% |
| Net Margin | 6.8% | -10.8% |
| Revenue YoY | -1.7% | 14.3% |
| Net Profit YoY | 10.5% | -330.2% |
| EPS (diluted) | $0.40 | $-1.50 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $493.8M | $295.4M | ||
| Q3 25 | $492.9M | $286.6M | ||
| Q2 25 | $468.8M | $288.1M | ||
| Q1 25 | $458.4M | $273.2M | ||
| Q4 24 | $502.4M | $258.4M | ||
| Q3 24 | $511.2M | $260.9M | ||
| Q2 24 | $504.3M | $271.9M | ||
| Q1 24 | $495.1M | $257.5M |
| Q4 25 | $33.7M | $-32.0M | ||
| Q3 25 | $71.7M | $21.6M | ||
| Q2 25 | $39.3M | $26.4M | ||
| Q1 25 | $20.7M | $24.5M | ||
| Q4 24 | $30.5M | $13.9M | ||
| Q3 24 | $19.4M | $19.8M | ||
| Q2 24 | $-153.0M | $26.7M | ||
| Q1 24 | $4.0M | $12.5M |
| Q4 25 | — | 42.1% | ||
| Q3 25 | — | 41.9% | ||
| Q2 25 | — | 43.3% | ||
| Q1 25 | — | 43.3% | ||
| Q4 24 | — | 42.3% | ||
| Q3 24 | — | 42.3% | ||
| Q2 24 | — | 43.8% | ||
| Q1 24 | — | 41.2% |
| Q4 25 | 9.9% | 11.2% | ||
| Q3 25 | 13.8% | 14.3% | ||
| Q2 25 | 12.8% | 15.9% | ||
| Q1 25 | 7.0% | 15.3% | ||
| Q4 24 | 7.8% | 12.5% | ||
| Q3 24 | 6.6% | 13.1% | ||
| Q2 24 | -31.3% | 17.7% | ||
| Q1 24 | 3.2% | 10.9% |
| Q4 25 | 6.8% | -10.8% | ||
| Q3 25 | 14.5% | 7.5% | ||
| Q2 25 | 8.4% | 9.2% | ||
| Q1 25 | 4.5% | 9.0% | ||
| Q4 24 | 6.1% | 5.4% | ||
| Q3 24 | 3.8% | 7.6% | ||
| Q2 24 | -30.3% | 9.8% | ||
| Q1 24 | 0.8% | 4.9% |
| Q4 25 | $0.40 | $-1.50 | ||
| Q3 25 | $0.84 | $1.01 | ||
| Q2 25 | $0.46 | $1.25 | ||
| Q1 25 | $0.24 | $1.15 | ||
| Q4 24 | $0.37 | $0.65 | ||
| Q3 24 | $0.23 | $0.94 | ||
| Q2 24 | $-1.84 | $1.27 | ||
| Q1 24 | $0.05 | $0.59 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $375.2M | $114.7M |
| Total DebtLower is stronger | $570.5M | $655.3M |
| Stockholders' EquityBook value | $865.9M | $1.5B |
| Total Assets | $2.2B | $2.7B |
| Debt / EquityLower = less leverage | 0.66× | 0.42× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $375.2M | $114.7M | ||
| Q3 25 | $340.1M | $132.9M | ||
| Q2 25 | $224.7M | $107.1M | ||
| Q1 25 | $99.0M | $240.3M | ||
| Q4 24 | $229.9M | $236.3M | ||
| Q3 24 | $103.8M | $206.9M | ||
| Q2 24 | $19.4M | $175.9M | ||
| Q1 24 | $8.0M | $163.9M |
| Q4 25 | $570.5M | $655.3M | ||
| Q3 25 | $577.2M | — | ||
| Q2 25 | $583.9M | — | ||
| Q1 25 | $590.5M | — | ||
| Q4 24 | $597.1M | $640.1M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | $644.9M |
| Q4 25 | $865.9M | $1.5B | ||
| Q3 25 | $890.7M | $1.5B | ||
| Q2 25 | $833.8M | $1.5B | ||
| Q1 25 | $789.2M | $1.5B | ||
| Q4 24 | $764.9M | $1.4B | ||
| Q3 24 | $732.5M | $1.5B | ||
| Q2 24 | $706.5M | $1.4B | ||
| Q1 24 | $856.2M | $1.4B |
| Q4 25 | $2.2B | $2.7B | ||
| Q3 25 | $2.2B | $2.4B | ||
| Q2 25 | $2.1B | $2.4B | ||
| Q1 25 | $2.0B | $2.5B | ||
| Q4 24 | $2.2B | $2.5B | ||
| Q3 24 | $2.1B | $2.5B | ||
| Q2 24 | $2.0B | $2.5B | ||
| Q1 24 | $2.2B | $2.5B |
| Q4 25 | 0.66× | 0.42× | ||
| Q3 25 | 0.65× | — | ||
| Q2 25 | 0.70× | — | ||
| Q1 25 | 0.75× | — | ||
| Q4 24 | 0.78× | 0.45× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 0.46× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $114.1M | — |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | 4.1% |
| Cash ConversionOCF / Net Profit | 3.39× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $114.1M | — | ||
| Q3 25 | $137.3M | $65.3M | ||
| Q2 25 | $137.2M | $52.2M | ||
| Q1 25 | $-117.5M | $21.0M | ||
| Q4 24 | $133.0M | $59.4M | ||
| Q3 24 | $91.8M | $54.0M | ||
| Q2 24 | $107.0M | $43.2M | ||
| Q1 24 | $-125.2M | $6.3M |
| Q4 25 | — | — | ||
| Q3 25 | — | $53.4M | ||
| Q2 25 | — | $42.3M | ||
| Q1 25 | — | $13.0M | ||
| Q4 24 | — | $49.1M | ||
| Q3 24 | — | $48.3M | ||
| Q2 24 | — | $38.3M | ||
| Q1 24 | — | $-1.9M |
| Q4 25 | — | — | ||
| Q3 25 | — | 18.6% | ||
| Q2 25 | — | 14.7% | ||
| Q1 25 | — | 4.8% | ||
| Q4 24 | — | 19.0% | ||
| Q3 24 | — | 18.5% | ||
| Q2 24 | — | 14.1% | ||
| Q1 24 | — | -0.7% |
| Q4 25 | — | 4.1% | ||
| Q3 25 | — | 4.2% | ||
| Q2 25 | — | 3.4% | ||
| Q1 25 | — | 2.9% | ||
| Q4 24 | — | 4.0% | ||
| Q3 24 | — | 2.2% | ||
| Q2 24 | — | 1.8% | ||
| Q1 24 | — | 3.2% |
| Q4 25 | 3.39× | — | ||
| Q3 25 | 1.91× | 3.02× | ||
| Q2 25 | 3.49× | 1.98× | ||
| Q1 25 | -5.66× | 0.86× | ||
| Q4 24 | 4.36× | 4.27× | ||
| Q3 24 | 4.72× | 2.73× | ||
| Q2 24 | — | 1.62× | ||
| Q1 24 | -31.03× | 0.50× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
MD
| Health Care Patient Service | $421.6M | 85% |
| Hospitals Contracts | $70.0M | 14% |
| Other | $2.2M | 0% |
NPO
| Sealing Technologies Segment | $187.0M | 63% |
| General Industrial | $71.3M | 24% |
| Power Generation | $19.9M | 7% |
| Oiland Gas Market | $15.0M | 5% |
| Semiconductors | $2.2M | 1% |
